These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18986025)

  • 21. Community acquired pneumonia and treatment priorities.
    Jagminas L
    Med Health R I; 2000 Dec; 83(12):396-8. PubMed ID: 11190130
    [No Abstract]   [Full Text] [Related]  

  • 22. Community-acquired pneumonia.
    Stein RT; Marostica PJ
    Paediatr Respir Rev; 2006; 7 Suppl 1():S136-7. PubMed ID: 16798540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Impact of the implementation of an intervention protocol in community-acquired pneumonia].
    Ramírez-Montesinos R; Moreno-Arias CV; Carulla-Aresté M; Pedrol-Clotet E
    Med Clin (Barc); 2012 Nov; 139(12):558-9. PubMed ID: 22698710
    [No Abstract]   [Full Text] [Related]  

  • 24. [Clinical efficacy of probiotics in complex treatment of called-up servicemen with community-acquired pneumonia].
    Rakov AL; Grinevich VB; Kriukov AE; Bogdanov IV; Rysev AV; Zakharchenko MM; Dobrenko VA; Gubonina IV
    Voen Med Zh; 2006 Apr; 327(4):15-22. PubMed ID: 16784101
    [No Abstract]   [Full Text] [Related]  

  • 25. Community acquired pneumonia.
    Lim WS
    Clin Med (Lond); 2004; 4(3):224-8. PubMed ID: 15244354
    [No Abstract]   [Full Text] [Related]  

  • 26. Legionellosis.
    Pedro-Botet ML; Sabrià M
    Semin Respir Crit Care Med; 2005 Dec; 26(6):625-34. PubMed ID: 16388431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibacterial drugs for community-acquired pneumonia.
    Med Lett Drugs Ther; 2021 Jan; 63(1616):10-14. PubMed ID: 33512346
    [No Abstract]   [Full Text] [Related]  

  • 28. Sparfloxacin empirical therapy in community-acquired pneumonia. Results of a meta-analysis of 2 comparative studies.
    Grassi GG; Brumpt I
    Drugs; 1995; 49 Suppl 2():406-8. PubMed ID: 8549379
    [No Abstract]   [Full Text] [Related]  

  • 29. The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model.
    Lodise TP; Tillotson GS; Spargo A; Bozkaya D; Massey J
    Clin Drug Investig; 2020 Oct; 40(10):961-971. PubMed ID: 32651832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does guideline adherence for empiric antibiotic therapy reduce mortality in community-acquired pneumonia?
    Aujesky D; Fine MJ
    Am J Respir Crit Care Med; 2005 Sep; 172(6):655-6. PubMed ID: 16148192
    [No Abstract]   [Full Text] [Related]  

  • 31. [The importance of other classical pyogenic pathogens (Staphylococcus aureus, gram negative bacteria and others) in community acquired pneumonia].
    Pachón J; Cordero E; Caballero FJ
    Med Clin (Barc); 1998 Feb; 110 Suppl 1():65-70. PubMed ID: 9717164
    [No Abstract]   [Full Text] [Related]  

  • 32. Modulating treatment according to resistance patterns and local epidemiology.
    J Assoc Physicians India; 2013 Jul; 61(7 Suppl):32-7. PubMed ID: 24779156
    [No Abstract]   [Full Text] [Related]  

  • 33. [Chlamydia pneumoniae and other Chlamydia species in community-acquired pneumonia].
    Ruiz Carmona M; Soler Polcar N; Torres Martí A
    Rev Clin Esp; 1998 Sep; 198 Suppl 1():30-4. PubMed ID: 9835771
    [No Abstract]   [Full Text] [Related]  

  • 34. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis.
    Dooley KE; Golub J; Goes FS; Merz WG; Sterling TR
    Clin Infect Dis; 2002 Jun; 34(12):1607-12. PubMed ID: 12032896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia.
    Covington PS; Davenport JM; Andrae DA; Stryjewski ME; Turner LL; McIntyre G; Almenoff J
    J Antimicrob Chemother; 2013 Nov; 68(11):2691-3. PubMed ID: 23749951
    [No Abstract]   [Full Text] [Related]  

  • 36. 13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents.
    Roig J; Casal J; Gispert P; Gea E
    Med Mal Infect; 2006; 36(11-12):680-9. PubMed ID: 17095177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia.
    Najib MM; Stein GE; Goss TF
    Pharmacotherapy; 2000 Apr; 20(4):461-9. PubMed ID: 10772376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia.
    Bhavnani SM; Ambrose PG
    Diagn Microbiol Infect Dis; 2008 Jan; 60(1):59-64. PubMed ID: 17889491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms.
    Goldstein RC; Husk G; Jodlowski T; Mildvan D; Perlman DC; Ruhe JJ
    Am J Infect Control; 2014 May; 42(5):539-41. PubMed ID: 24773792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of different empirical antibiotic treatment regimens for community-acquired pneumonia on the emergence of Clostridium difficile.
    Bruns AH; Oosterheert JJ; Kuijper EJ; Lammers JW; Thijsen S; Troelstra A; Hoepelman AI
    J Antimicrob Chemother; 2010 Nov; 65(11):2464-71. PubMed ID: 20823105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.